Is Novavax Stock a Buy?
With a mouth-watering return of 1,770% in the past year, Novavax (NASDAQ: NVAX) is undoubtedly the best-performing coronavirus stock on the market. The company total return growth was nearly triple competitor Moderna's, which already has a vaccine on the market, over the same period.
On Jan. 28, Novavax announced efficacy data in two late-stage trials for its protein-based coronavirus vaccine candidate, NVX-CoV2373. This is just what the company needed to keep its momentum going. Here's how it could reach new all-time highs.
Image source: Getty Images.
Source Fool.com
